CAPR logo

Capricor Therapeutics Inc. (CAPR)

$8.30

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CAPR

Market cap

$482579546

EPS

-2.64

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

0.798064

Price on CAPR

Previous close

$9.53

Today's open

$9.35

Day's range

$8.19 - $9.35

52 week range

$2.96 - $40.37

Profile about CAPR

CEO

Linda Marbn

Employees

231

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

58142114

Issue type

Common Stock

CAPR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CAPR

Capricor Stock Rises: What's Going On?

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are rising Tuesday. Traders seemingly position ahead of the FDA's pending decision on its Duchenne muscular dystrophy therapy, deramiocel.

news source

Benzinga • an hour ago

news preview

Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss

Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trading higher Wednesday despite the company missing earnings per share estimates in its third-quarter results Tuesday after the market closed.

news source

Benzinga • Nov 11, 2026

news preview

Capricor Therapeutics Q3 Earnings Call Highlights

Capricor Therapeutics NASDAQ: CAPR is awaiting a Nov. 22 Food and Drug Administration decision on Deramiocel for Duchenne muscular dystrophy, as the company prepares for a potential launch while reporting a wider third-quarter loss.

news source

MarketBeat • Nov 11, 2026

news preview

Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript

Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 11, 2026

news preview

Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Capricor's HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology

SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the abstract presenting cardiac results from the Company's HOPE-3 Phase 3 trial of Deramiocel in Duchenne muscular dystrophy (DMD) received the Outstanding Research Award in Pediatric Cardiology at the American Heart Association (AHA) Scientific Sessions 2026 on Saturday, November 7, in Chicago. The presentation included new cardiac MRI data on myocardial fibrosis, measured by late gadolinium enhancement (LGE), and a comparison with matched patients not treated with Deramiocel from a natural history dataset.

news source

GlobeNewsWire • Nov 9, 2026

news preview

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics  (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Management will host a conference call and webcast at 4:30 p.m.

news source

GlobeNewsWire • Nov 3, 2026

news preview

Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears

Capricor Therapeutics NASDAQ: CAPR presented updated clinical data for deramiocel in Duchenne muscular dystrophy, or DMD, including two-year open-label extension results from its Phase III HOPE-3 study and additional statistical analyses submitted to the U.S. Food and Drug Administration.

news source

MarketBeat • Oct 7, 2026

news preview

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript

news source

Seeking Alpha • Oct 8, 2026

news preview

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress

-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year- -At 24 Months, Both Groups Showed Slower Decline in Upper Limb Function Than Natural History Predicts- -Data Included in Deramiocel BLA Major Amendment; PDUFA Target Action Date November 22, 2026- -Webinar Scheduled for October 7, 2026, at 1:00 p.m. ET in Collaboration with PPMD to Discuss the Data- SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive new data from its ongoing HOPE-3 open-label extension (OLE) study for its lead asset, Deramiocel, for the treatment of upper limb impairment in Duchenne muscular dystrophy (DMD).

news source

GlobeNewsWire • Oct 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Capricor Therapeutics Inc.

Open an M1 investment account to buy and sell Capricor Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CAPR on M1